In Berger Montague Whistleblower Case, Janssen Found Liable for Illegal Off-Label Promotion, Marketing of 2 HIV/AIDS-Treatment Drugs - Judgment Could Exceed $1B
July 18, 2024
July 18, 2024
PHILADELPHIA, Pennsylvania, July 18 -- Berger Montague, a law firm, issued the following news:
Berger Montague PC is pleased to announce that on June 13, 2024, a jury unanimously found Johnson & Johnson subsidiary Janssen Products, LP liable for illegal off-label promotion and marketing of two of its HIV/AIDS-treatment drugs, in violation of the federal False Claims Act and state False Claims Acts. The jury of eight unanimously agreed that Janssen was responsible for defrauding . . .
Berger Montague PC is pleased to announce that on June 13, 2024, a jury unanimously found Johnson & Johnson subsidiary Janssen Products, LP liable for illegal off-label promotion and marketing of two of its HIV/AIDS-treatment drugs, in violation of the federal False Claims Act and state False Claims Acts. The jury of eight unanimously agreed that Janssen was responsible for defrauding . . .